Compare ORRF & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ORRF | FTRE |
|---|---|---|
| Founded | 1919 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 699.5M | 829.3M |
| IPO Year | 1995 | 2023 |
| Metric | ORRF | FTRE |
|---|---|---|
| Price | $35.11 | $13.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $42.00 | $14.06 |
| AVG Volume (30 Days) | 80.6K | ★ 1.5M |
| Earning Date | 04-21-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | ★ 182.43 | N/A |
| EPS | ★ 1.12 | N/A |
| Revenue | $37,144,000.00 | ★ $2,723,400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.15 | $3.09 |
| P/E Ratio | $32.06 | ★ N/A |
| Revenue Growth | ★ 36.00 | 1.00 |
| 52 Week Low | $29.31 | $3.97 |
| 52 Week High | $40.72 | $18.67 |
| Indicator | ORRF | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 38.51 | 59.26 |
| Support Level | $34.51 | $8.85 |
| Resistance Level | $35.99 | $18.26 |
| Average True Range (ATR) | 0.87 | 0.82 |
| MACD | -0.21 | 0.07 |
| Stochastic Oscillator | 11.81 | 54.77 |
Orrstown Financial Services Inc is a financial holding company. Through its subsidiaries, it operates in the community banking segment and engages in lending activities, including commercial, residential, commercial mortgages, construction, municipal, and various forms of consumer lending and deposit services, including checking, savings, time, and money market deposits. The Group also provides fiduciary, investment advisory, insurance, and brokerage services. It offers services to individuals, professionals, small businesses, and other enterprises across different locations in the United States through its branch network and client service centers.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.